Depleting Tumor Cells Expressing Immune Checkpoint Ligands—A New Approach to Combat Cancer

Antibodies against inhibitory immune checkpoint molecules (ICPMs), referred to as immune checkpoint inhibitors (ICIs), have gained a prominent place in cancer therapy. Several ICIs in clinical use have been engineered to be devoid of effector functions because of the fear that ICIs with preserved ef...

Descripción completa

Detalles Bibliográficos
Autores principales: Marcucci, Fabrizio, Rumio, Cristiano
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069236/
https://www.ncbi.nlm.nih.gov/pubmed/33921301
http://dx.doi.org/10.3390/cells10040872

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8069236/
https://www.ncbi.nlm.nih.gov/pubmed/33921301
http://dx.doi.org/10.3390/cells10040872

Ejemplares similares